Orca-T for GVHD–free survival and Understanding VEXAS anemia
About this episode
This episode features an interview with Drs. Everett Meyer and Olivier Hermine discussing their research on Orca-T and VEXAS anemia.
In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Everett Meyer and Olivier Hermine on their latest articles published in volume 147 issue 11 of Blood . Dr. Everett Meyer discusses " Orca-T vs allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial " which demonstrated that Orca-T showed superior chronic GVHD–free survival compared to the control arm (78.0% vs 38.4%, P < .001) and lower nonrelapse mortality (3.4% vs 13.2%, P = .03). Dr. Olivier Hermine shares insights from " VEXAS anemia is a mosaic erythroblastopenia " which proposes that VEXAS syndrome–associated anemia should be considered as a mosaic erythroblastopenia, in which the severity of anemia is influenced by the quality and quantity of the UBA1 –wild-type compartment.
More episodes of Blood Podcast
- IV Iron during Acute Infection and Revisiting iTTP Refractoriness
- A Pediatric ITP Risk Model and Targeting CD2 with CAR T-cell therapies
- IV Iron Risks and Low-Dose AML Gains
- Treating AML, Before and After Relapse
Explore listener stats, chart rankings, contacts and more on the Blood Podcast podcast page.